NCI-41356, a promising small inhibitor of HSPB5 in idiopathic pulmonary fibrosis? - 17/02/23

Doi : 10.1016/j.rmr.2022.11.068 
J. Tanguy 1, , P.-M. Boutanquoi 1, L. Dondaine 1, O. Burgy 1, P.-S. Bellaye 1, G. Beltramo 1, 2, C. Garrido 1, P. Bonniaud 1, 2, F. Goirand 1
1 Inserm U1231, UFR des sciences de santé, Dijon, France 
2 Reference center for rare lung diseases, CHU Dijon, Dijon, France 

Corresponding author.



Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal disease of unknown aetiology. In France, it ranks among the most frequent interstitial pathologies and affects 6 out of 8 people per 100,000 each year. IPF is characterized by dysregulated healing mechanisms that leads to the accumulation of large amounts of collagen in the lung tissue that disrupts the alveolar architecture. Nintedanib and Pirfenidone are the only currently available treatments even though they are only able to slow down the disease without being curative. In this context, inhibiting HSPB5, a low molecular weight heat shock protein known to be involved in the development of fibrosis, could constitute a potential therapeutic target. Our aim consist to explore how NCI-41356 (a chemical inhibitor of HSPB5) can limit the development of pulmonary fibrosis.


In vivo, fibrosis was assessed in mice injected intratracheally (i.t.) with Bleomycin (BLM) and treated with NaCl or NCI-41356 (3 times i.t. or 3 times a week i.v.). Fibrosis was evaluated by collagen quantification (Sircol, Sirius Red staining), Immunofluorescence, TGF-β gene expression (RNAscope). In vitro, TGF-β1 signaling was evaluated in epithelial cells treated by TGF-β1 with or without NCI-41356 (Western Blot, Immunofluorescence, Proximity ligation assay).


In vivo, NCI-41356 reduced the accumulation of collagen, the expression of TGF-β1 and several pro-fibrotic markers (PAI-1, α-SMA). In vitro, NCI-41356 decreased the interaction between HSPB5 and SMAD4 explaining NCI-41356 anti-fibrotic properties.


In this study, we determined that inhibition of HSPB5/SMAD4 could limit IPF in mice. NCI-41356 modulates SMAD4 nuclear translocation thus limiting TGF-β1 signaling and synthesis of collagen and pro-fibrotic markers. Further investigations with human fibrotic lung tissues are needed to determine if these results can be transposed in human.

El texto completo de este artículo está disponible en PDF.


© 2022  Publicado por Elsevier Masson SAS.

    Exportación citas

  • Fichero

  • Contenido

Vol 40 - N° 2

P. 145 - février 2023 Regresar al número
Artículo precedente Artículo precedente
  • HSP90 comme biomarqueur et cible thérapeutique dans la fibrose pulmonaire idiopathique
  • A.-R. Garnier, J. Tanguy, H. Sikner, A. Bouchard, M. Moreau, M. Claron, P. Bonniaud, B. Collin, F. Goirand, P.-S. Bellaye
| Artículo siguiente Artículo siguiente
  • Quantification of lung fibrosis in COVID-19 related and -unrelated ARDS
  • L. Gerard, M. Lecocq, G. Courtoy, C. Bouzin, T. Plante-Bordeneuve, C. Pilette

¿Ya suscrito a @@106933@@ revista ?